Daniel Skovronsky, Eli Lilly's Chief Scientific Officer, Appointed to Illumina's Board of Directors
核心洞察
Daniel M. Skovronsky, MD, PhD, Chief Scientific and Product Officer of Eli Lilly and President of Lilly Research Laboratories, has been appointed to Illumina's Board of Directors effective June 16, 2026.
Dr. Skovronsky brings extensive experience in drug discovery, clinical development, and translational medicine to Illumina's work advancing genomics and multiomics platforms.
Illumina CEO Jacob Thaysen highlighted that Skovronsky's leadership in building large research portfolios will strengthen the company's innovation across genomics, multiomics, and precision medicine.
Illumina, Inc. (NASDAQ: ILMN) announced on June 23, 2026, the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky, who currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, brings decades of leadership in drug discovery, clinical development, and translational medicine to the genomics and multiomics technology company.
"Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare impact," said Jacob Thaysen, chief executive officer of Illumina. "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."
A Career Spanning Academia and Industry
Dr. Skovronsky's career trajectory reflects deep integration of academic medicine and pharmaceutical entrepreneurship. He received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania. He completed residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania.
In 2004, Skovronsky founded Avid Radiopharmaceuticals (搜索), where he served as Chief Executive Officer until its acquisition by Eli Lilly in 2010. Following the acquisition, he joined Lilly and has since held roles of increasing responsibility across the organization. In his current position, he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.
Strengthening the Intersection of Pharma R&D and Genomics
The appointment signals Illumina's strategic interest in deepening ties between pharmaceutical research and development and its genomics and multiomics platforms. Dr. Skovronsky's experience in translational medicine — bridging laboratory discoveries with clinical applications — aligns directly with Illumina's focus on applications in the life sciences, oncology, reproductive health, and other emerging segments.
Prior to this appointment, Dr. Skovronsky served on the Board of Directors of Myriad Genetics, Inc. (搜索), further demonstrating his engagement with the genomics and precision medicine sector.
About Illumina
Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments, with a mission to improve human health by unlocking the power of the genome.